Zydus Cadila gets USFDA nod to make drug for treating dementia
DSIJ Intelligence / 01 Sep 2017
Donepezil Hydrochloride Tablet, in the strength of 23 mg, used to treat dementia related to Alzheimer’s, will be marketed by Zydus Cadila in the wake of receiving the final approval from the USFDA.
Donepezil Hydrochloride Tablet, in the strength of 23 mg, used to treat dementia related to Alzheimer’s, will be marketed by Zydus Cadila in the wake of receiving the final approval from the USFDA. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04. Meanwhile, the stock was trading up by 2.08% at Rs 510.50 per share on the BSE at 1127 hours. It opened at Rs 502.75 per share and touched its intraday high and low at Rs 512.60 and Rs 502.55 per share.
The stock has attracted a total traded volume of 5,24,973 shares and traded value of Rs 2,674.89 lakh on the NSE at 1124 hours. The stock’s 52 week high stood at Rs 560 as on July 10, 2017 and low at Rs 328.80 per share as on December 23, 2016.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.